MEGAN PERRY: Open Payments
NPI 1811762016 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$420 in 18 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $538 · 2025 $420
Food & beverage: $420
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 5 | $154 |
| GlaxoSmithKline, LLC. | 4 | $81 |
| Optinose US, Inc. | 3 | $60 |
| Genentech USA, Inc. | 2 | $48 |
| ALK-Abello, Inc | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: DUPIXENT, NUCALA, Xhance, Xolair, Grastek, NEFFY, PYRUKYND, BREZTRI.
Industry payments across VA — which companies pay providers there.
